» Articles » PMID: 26087310

Mitochondrial Biogenesis is Required for the Anchorage-independent Survival and Propagation of Stem-like Cancer Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Jun 19
PMID 26087310
Citations 148
Authors
Affiliations
Soon will be listed here.
Abstract

Here, we show that new mitochondrial biogenesis is required for the anchorage independent survival and propagation of cancer stem-like cells (CSCs). More specifically, we used the drug XCT790 as an investigational tool, as it functions as a specific inhibitor of the ERRα-PGC1 signaling pathway, which governs mitochondrial biogenesis. Interestingly, our results directly demonstrate that XCT790 efficiently blocks both the survival and propagation of tumor initiating stem-like cells (TICs), using the MCF7 cell line as a model system. Mechanistically, we show that XCT790 suppresses the activity of several independent signaling pathways that are normally required for the survival of CSCs, such as Sonic hedgehog, TGFβ-SMAD, STAT3, and Wnt signaling. We also show that XCT790 markedly reduces oxidative mitochondrial metabolism (OXPHOS) and that XCT790-mediated inhibition of CSC propagation can be prevented or reversed by Acetyl-L-Carnitine (ALCAR), a mitochondrial fuel. Consistent with our findings, over-expression of ERRα significantly enhances the efficiency of mammosphere formation, which can be blocked by treatment with mitochondrial inhibitors. Similarly, mammosphere formation augmented by FOXM1, a downstream target of Wnt/β-catenin signaling, can also be blocked by treatment with three different classes of mitochondrial inhibitors (XCT790, oligomycin A, or doxycycline). In this context, our unbiased proteomics analysis reveals that FOXM1 drives the expression of >90 protein targets associated with mitochondrial biogenesis, glycolysis, the EMT and protein synthesis in MCF7 cells, processes which are characteristic of an anabolic CSC phenotype. Finally, doxycycline is an FDA-approved antibiotic, which is very well-tolerated in patients. As such, doxycycline could be re-purposed clinically as a 'safe' mitochondrial inhibitor, to target FOXM1 and mitochondrial biogenesis in CSCs, to prevent tumor recurrence and distant metastasis, thereby avoiding patient relapse.

Citing Articles

Estrogen-related receptor alpha (ERRα) controls the stemness and cellular energetics of prostate cancer cells via its direct regulation of citrate metabolism and zinc transportation.

Ma T, Xie W, Xu Z, Gao W, Zhou J, Wang Y Cell Death Dis. 2025; 16(1):154.

PMID: 40044646 PMC: 11882781. DOI: 10.1038/s41419-025-07460-z.


Mitochondrial unfolded protein response-dependent β-catenin signaling promotes neuroendocrine prostate cancer.

Woytash J, Kumar R, Chaudhary A, Donnelly C, Wojtulski A, Bethu M Oncogene. 2024; .

PMID: 39690273 DOI: 10.1038/s41388-024-03261-4.


High expression of BBOX1 in paracancerous tissue is associated with poor prognosis in hepatocellular carcinoma patients.

Fang R, Zhan Y, Dong X, Li S, Yang M, Zhao Y Sci Rep. 2024; 14(1):28413.

PMID: 39557956 PMC: 11574014. DOI: 10.1038/s41598-024-78127-6.


Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells.

Krawczynska N, Wang Y, Lim K, Das Gupta A, Lenczowski A, Abughazaleh M bioRxiv. 2024; .

PMID: 39131340 PMC: 11312600. DOI: 10.1101/2024.08.02.606061.


Cancer stem cells: advances in knowledge and implications for cancer therapy.

Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z Signal Transduct Target Ther. 2024; 9(1):170.

PMID: 38965243 PMC: 11224386. DOI: 10.1038/s41392-024-01851-y.


References
1.
Fisher K, Das B, Kortum R, Chaika O, Lewis R . Kinase suppressor of ras 1 (KSR1) regulates PGC1α and estrogen-related receptor α to promote oncogenic Ras-dependent anchorage-independent growth. Mol Cell Biol. 2011; 31(12):2453-61. PMC: 3133429. DOI: 10.1128/MCB.05255-11. View

2.
Lamb R, Harrison H, Hulit J, Smith D, Lisanti M, Sotgia F . Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. Oncotarget. 2014; 5(22):11029-37. PMC: 4294326. DOI: 10.18632/oncotarget.2789. View

3.
Wu F, Wang J, Wang Y, Kwok T, Kong S, Wong C . Estrogen-related receptor alpha (ERRalpha) inverse agonist XCT-790 induces cell death in chemotherapeutic resistant cancer cells. Chem Biol Interact. 2009; 181(2):236-42. DOI: 10.1016/j.cbi.2009.05.008. View

4.
Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O . Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat. 2008; 114(1):47-62. DOI: 10.1007/s10549-008-9982-8. View

5.
Gemenetzidis E, Elena-Costea D, Parkinson E, Waseem A, Wan H, Teh M . Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res. 2010; 70(22):9515-26. PMC: 3044465. DOI: 10.1158/0008-5472.CAN-10-2173. View